Article
|
Open Access
Featured
-
-
Perspective |
Practical recommendations for using ctDNA in clinical decision making
This Perspective reviews the utility and interpretation of circulating tumour DNA for the detection of residual and recurrent cancers and provides recommendations regarding its clinical application for a variety of solid tumours.
- Stacey A. Cohen
- , Minetta C. Liu
- & Alexey Aleshin
-
Article |
Unified rhombic lip origins of group 3 and group 4 medulloblastoma
Multi-omic mapping shows that group 3 and group 4 medulloblastomas have a common, human-specific developmental origin in the cerebellar rhombic lip, providing a basis for their ambiguous molecular features and overlapping anatomical location, and for the difficulty of modelling these tumours in mice.
- Kyle S. Smith
- , Laure Bihannic
- & Paul A. Northcott
-
Article |
Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer
Deep whole-genome sequencing of serial blood samples and matched metastatic tissue reveals that circulating tumour DNA profiling enables detailed study of treatment-driven subclone dynamics, epigenomics and genome-wide somatic evolution in metastatic human cancers.
- Cameron Herberts
- , Matti Annala
- & Alexander W. Wyatt
-
Article
| Open AccessMulti-omic machine learning predictor of breast cancer therapy response
Integration of pre-treatment tumour features in predictive models using machine learning could inform on response to therapy.
- Stephen-John Sammut
- , Mireia Crispin-Ortuzar
- & Carlos Caldas
-
Letter |
Tumour lineage shapes BRCA-mediated phenotypes
Analysis of more than 17,000 tumours suggests that the contribution of germline and somatic mutations in the BRCA1 and BRCA2 genes to oncogenesis depends on tumour lineage.
- Philip Jonsson
- , Chaitanya Bandlamudi
- & Barry S. Taylor
-
Letter |
Genome-wide cell-free DNA fragmentation in patients with cancer
Analyses of fragmentation patterns of cell-free DNA in the blood of patients with cancer and healthy individuals using a machine learning algorithm provide a proof-of principle approach for the early detection and screening of human cancer.
- Stephen Cristiano
- , Alessandro Leal
- & Victor E. Velculescu
-
Letter |
Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring
A systematic proteomic investigation of disease mediators secreted by pancreatic stellate cells identifies leukaemia inhibitory factor (LIF) as a key factor that acts on cancer cells, promoting tumour progression and chemoresistance.
- Yu Shi
- , Weina Gao
- & Tony Hunter
-
Letter |
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
In humans, TGFβ signalling is associated with lack of response to immunotherapy in immune-excluded tumours; in mouse models of this immune phenotype, robust tumour infiltration by T cells and tumour regression are observed only when checkpoint inhibition is combined with inhibition of TGFβ signalling.
- Sanjeev Mariathasan
- , Shannon J. Turley
- & Thomas Powles
-
Article |
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
The clinical benefit of anti-PD-1 antibody treatment is dependent on the extent to which exhausted CD8 T cells are reinvigorated in relation to the tumour burden of the patient.
- Alexander C. Huang
- , Michael A. Postow
- & E. John Wherry
-
Spotlight |
Spotlight on Cancer
-
Letter |
A 17-gene stemness score for rapid determination of risk in acute leukaemia
A rapid gene signature test (LSC17) that captures stem cell expression programs in acute myeloid leukaemia patients at diagnosis is associated with therapy response and survival, facilitating initial treatment stratification.
- Stanley W. K. Ng
- , Amanda Mitchell
- & Jean C. Y. Wang
-
Analysis |
Inconsistency in large pharmacogenomic studies
This Analysis compares two large-scale pharmacogenomic data sets that catalogued the sensitivity of a large number of cancer cell lines to approved and potential drugs, and finds that whereas the gene expression data are largely concordant between the two studies, the reported drug sensitivity measures and subsequently their association with genomic features are highly discordant.
- Benjamin Haibe-Kains
- , Nehme El-Hachem
- & John Quackenbush
-
Article |
Systematic identification of genomic markers of drug sensitivity in cancer cells
Human cancer cell lines are screened with drugs, undergoing clinical or preclinical investigation, to determine specific genomic alterations associated with response to therapeutic agents.
- Mathew J. Garnett
- , Elena J. Edelman
- & Cyril H. Benes
-
Outlook |
Diagnostics: The early bird
Identifying the patients most likely to progress from a precancerous condition to multiple myeloma could help doctors catch the disease early and stop it taking hold.
- Lauren Gravitz
-
Letter |
Adherens junction protein nectin-4 is the epithelial receptor for measles virus
Nectin-4 is identified as a receptor for measles virus on epithelial cells, and measles virus might use nectin-4 for emergence in the airways.
- Michael D. Mühlebach
- , Mathieu Mateo
- & Roberto Cattaneo
-
Outlook |
Biomarkers: Portents of malignancy
Being able to determine an individual's chances of developing cancer will greatly improve risk management strategies and recruitment to clinical trials.
- Vicki Brower
-
Letter |
Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271
In this work, the neural crest stem cell marker CD271 is implicated as a cancer stem cell marker, allowing identification and prospective isolation of melanoma cancer stem cells.
- Alexander D. Boiko
- , Olga V. Razorenova
- & Irving L. Weissman
-
News & Views |
Invitation to a second round
Tumour cells are non-uniform. The question is whether a distinct subpopulation of the cells drives tumour growth and generates cellular variation. To answer this, the data must be interpreted carefully.
- Peter Dirks
-
Technology Feature |
MicroRNAs as biomarkers
-
Research Highlights |
Cancer detection: Tracking roving cancer cells
-
News |
Personalized biomarkers monitor cancer
Pilot study harnesses sequencing power to track tumours.
- Heidi Ledford